Aeglea BioTherapeutics (AGLE) Stock Highlights

20.09 | +4.09%

2023-12-28 14:34:51

Aeglea BioTherapeutics Inc is a clinical-stage biotechnology company. It designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The companys lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in an early clinical development stage.

Statistics

Range Today

18.61 20.32

Volume Today 93.58K

Range 1 Year

0.11 22.66

Volume 1 Year 469.64M

Range 3 Year

0.11 22.66

Volume 3 Year 849.15M

Range 10 Year

0.11 22.66

Volume 10 Year 1.01B

Highlights

Market Capitalization 48.63M (micro)

Floating Shares 1.92M

Current Price 20.09

Price To Earnings -0.15

Price To Revenue 220.24

Earnings Per Share -74.15

Payout Ratio 0%

Performance

Latest +4.09%

1 Month +85.85%

3 Months +73.34%

6 Months +5480.56%

1 Year +5051.28%

3 Years +145.3%

5 Years +152.7%

10 Years +100.9%

Benchmarks

Market Capitalization

294 / 368

Gross Profits

154 / 278

Total Revenue

235 / 300

Total Rank

283 / 368

Free Cashflow

53 / 352

Performance 5 years

58 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.